



My research focuses on atherosclerosis. Since the beginning of my career, I have published over 80 scientific articles in highly regarded journals and books, and have presented my achievements at many international

scientific conferences.

I am also a member of The International Society for Atherosclerosis and The European Atherosclerosis Society and the American Heart Association, and was recognized in 1995 a “Young Leading Investigator” both by the International Society of “Drug Affecting Lipid Metabolism” and the “Yoshida Heart Institute” in Japan. I have also served as consultant, collaborator and board member for numerous pharmaceutical and biotechnology companies in Israel, the USA and Europe.

I am a co-inventor of the subject matter described and claimed in the above-referenced U.S. Patent Application.

I have read the Official Actions issued with respect to the above-identified application.

The Examiner has stated that the present invention of a composition for an immunological oral-tolerance inducing composition for the prevention and/or treatment of atherosclerosis is anticipated by, and would have been obvious to one of ordinary skill in the art in view of the referenced prior art. I am of the opinion that the prior art does not anticipate, nor provides motivation for one of ordinary skill in the art to combine the teachings of Strober et al. with Hansson et al., Resch et al. and Sima, et al., and that the scope and content of the prior art, which discloses a method for enhancement of oral tolerance to autoimmune diseases (Strober et al.) and the presence of anti-oxidized LDL antibodies in atherosclerosis (Hansson et al., Resch et al. and Sima et al.) are greatly distinguished from and dissimilar to the present invention.

The present invention is of a unique oral-tolerance inducing composition which is not only novel and nonobvious, but provides an unexpected and previously unavailable basis for prevention and/or treatment of atherosclerosis, and as such responds to a long-felt need in the field of cardiology and preventive medicine.

Strober et al. teaches enhancing oral tolerance to an antigen by suppressing the proinflammatory cytokine IL-12, specifically for the treatment of autoimmune disease. As discussed in detail in the accompanying response to Official Action, atherosclerosis is primarily a disease of deranged lipid metabolism, which does not exhibit the hallmark flare and remission of autoimmune disease, does not respond to conventional immune suppression, and is therefore not commonly classified as an autoimmune disease. Thus, although Hansson et al., Resch et al. and Sima, et al. do teach the presence of anti-oxidized LDL antibodies in atherosclerosis, the significance of Ox LDL to the pathogenesis of atherosclerosis, at the time the invention was made, remained unclear and controversial. For example, in contrast to classic response to autoantigens, it was well known in the art that OxLDL can induce atherosclerosis, while anti-OxLDL antibodies conferred partial protection. Further confounding understanding of the role of OxLDL and potential therapeutic applications is the often-repeated fact of regular dietary intake of significant amounts of OxLDL in cooked animal products.

Applicant has submitted a series of drawings, illustrating the possible effects of oral administration of an antigen on progression of atherosclerosis. As detailed in the accompanying response, and hereinabove, the illustrations depict the inability to infer, without extensive experimentation, which formulations, doses or regimen of treatment will result in induction of oral tolerance (hyporesponsiveness, Panel I, and Oral Tolerance, Panel II), and, on the other hand, which will further stimulate inflammatory response of the gut associated lymph tissue (GALT) (hyperresponsiveness, Panel II), exacerbating disease. One example of such inflammatory immune response to oral feeding of a well known autoantigen is described in Blanas E, et al. (Science 1996;274:1710, enclosed herewith).

Among the criteria applied to determine non-obviousness of an invention is demonstration of unexpected results. While reducing the present invention to practice, employing the methodology disclosed in the instant

specification, we have unexpectedly uncovered further aspects of the prevention and/or treatment of atherosclerosis by oral feeding with Ox LDL, strengthening this unique and novel approach to the disease.

Specifically, in one experiment a dose-dependent reduction in atherosclerotic lesions in genetically susceptible (LDL-RD and Apo-E “knock out”) mice was observed following oral administration of Ox LDL according to the methods of the present invention, thus further confirming the range of “therapeutically effective amount” disclosed in the instant specification. Within the range of 10-1000 μg per mouse, the strongest effect on atherogenesis (45 % reduction in lesions) was observed at a dose of 100 μg /mouse. In another important series of experiments, a significant, dose-dependent reduction of T-cell proliferation in lymph nodes of LDL-RD and Apo-E “knock out” mice following oral administration of Ox LDL according to the methods of the present invention was observed. Whereas oral administration of as little as 10 μg /mouse Ox LDL produced a 49 % inhibition of proliferation of Ox LDL-responsive lymphocytes, indicating the ability of orally administered Ox LDL to induce tolerance by clonal anergy/deletion of specific lymphocyte populations. In yet a further series of experiments, immune tissue-specific suppression of the pro-inflammatory cytokine $\text{INF}\gamma$, and induction of the anti-inflammatory, Th-2 specific cytokine IL-10 were observed in LDL-RD and Apo-E “knock out” mice following oral administration of Ox LDL according to the methods of the present invention. Such a demonstration of immune modulation by oral administration of Ox LDL now provides the basis for determining therapeutically effective compositions and doses of Ox LDL of the present invention.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or

imprisonment, or both, under Section 1001 of Title 18 of the United states Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

November 21, 2002

A handwritten signature in dark ink, appearing to read "D. Harats", is written over a horizontal line.

Prof. Dror Harats

Enc.:

CV of Prof. Dror Harats

Drawings illustrating GALT Immune Response: Panel I and Panel II

Copy of Blanas, E et al. Science 1996;274:1710.

CURRICULUM VITAE

Name: Dror Harats M.D. **Identity No.:** 5449664-1

Place of work: The Sheba Medical Center **Phone No.:** (03)5302940
Tel Hashomer, 52621

Faculty/Hospital: The Sheba Medical Center **Department:** The Institute
Tel Hashomer, 52621 of Lipid and Atherosclerosis
Research.

Home Address: 71 Mendes St., Ramat-Gan **Phone No.:** (03)5357650

Date & Place of Birth: 17/7/56 Israel

ZAHAL Military Service: Enlisted: February, 1982.
Discharged: February, 1985.

Marital Status: married **No. of Children:** 2

A. EDUCATION

<u>Period of Study</u>	<u>Name of University</u>	<u>Subject</u>	<u>Degree</u>	<u>Date</u>
1974-1981	Hebrew University-Hadassah Medical School, Jerusalem, Israel.	Medicine	M.D.	1982

Specialization Certificate: Internal Medicine: (1989)
Pulmonary Medicine: (1995)

M.D., Thesis: Non-Invasive Evaluation of Complete Left
Bundle Branch Block, 1982.

Name of Supervisor: Prof. Alexander Batler, Sackler Faculty of
Medicine, Tel Aviv University.

B. FURTHER STUDIES

<u>Period of Study</u>	<u>Name of University</u>	<u>Subject & Degree</u>	<u>Date</u>
1985-1989	Hebrew University-Hadassah Medical School, Jerusalem, Israel.	Specialization in internal Medicine.	1989
1991-1994	The University of California San Francisco San Francisco, USA.	Specialization in Pulmonary & Critical Care Medicine.	1994
1992-1994	The University of California San Francisco San Francisco, USA.	Postdoctorate Molecular Genetics.	1994

C. ACADEMIC EXPERIENCE

<u>Period</u>	<u>Name of Institution</u>	<u>Department</u>	<u>Rank/Function</u>
2001-	Sheba Medical Center Tel-Hashomer, Israel.	Basic Research Committee	member of the committee
1999-	Sackler School of Med., Tel Aviv University, Israel	Internal Medicine	Associate Professor
1998-	Sheba Medical Center Tel-Hashomer, Israel.	Helsinki- IRB Committee	Head of the committee
1996-	Sheba Medical Center Tel-Hashomer, Israel.	Institute of Lipid and Atherosclerosis Research.	Head of the Institute
1995-1999	Sackler School of Med., Tel Aviv University, Israel	Internal Medicine	Senior lecturer
1994-1996	Sheba Medical Center Tel-Hashomer, Israel.	Institute of Lipid And Atherosclerosis Research.	Senior Scientist & Physician.
1992-1994	Syntex Discovery Research Palo-Alto, California, USA.	Molecular Genetics.	Visiting Scientist
1991-1994	The University of Ca. San Francisco, USA.	Cardiovascular Research Institute.	Postdoctorate
1990-1995	Hebrew University Hadassah Medical School, Jerusalem, Israel.	Internal Medicine	Lecturer
1987-1990	Hebrew University Hadassah Medical School, Jerusalem, Israel.	Internal Medicine	Instructor

D. CLINICAL EXPERIENCE

<u>Period</u>	<u>Name of Institution</u>	<u>Department</u>	<u>Rank/Function</u>
1996-	Sheba Medical Center Tel-Hashomer, Israel.	Institute of Lipid And Atherosclerosis Research.	Head of the Institute
1994-1996	Sheba Medical Center Tel-Hashomer, Israel.	Institute of Lipid And Atherosclerosis Research.	Attending Physician
1994-	Sheba Medical Center Tel-Hashomer, Israel.	Institute of Pulmonary Medicine.	Attending Physician
1991-1994	The University of California San Francisco San Francisco, USA.	Pulmonary & Critical Care Medicine	Fellow
1989-1991	Hebrew University Hadassah Medical School, Jerusalem, Israel.	Internal Medicine	Attending Physician
1987-1991	Ministry of Defense.	Rehabilitation	District Physician.
1985-1989	Hebrew University Hadassah Medical School, Jerusalem, Israel.	Internal Medicine	Resident
1982-1985	ZAHAL	The Medical Forces	Captain
1981-1982	Sheba Medical Center Tel Hashomer, Israel.	Rotating Internship	Intern

Boards & Licenses

VQE-ECFMG, 1981.
 ECFMG #328-876-8, 1981.
 Israel, Medical License #017264, 1984.
 Israel-Boards of Internal Medicine, part 1 & 2, with distinction, 1988 & 1989.
 Internal Medicine #10791, 1989.
 FLEX #000088768 part 1 and 2, 1993.
 Nebraska, license to practice medicine #19509, 1994.
 Israel-Board in Pulmonary Medicine, part 1 & 2, 1995.

E. ACADEMIC & PROFESSIONAL AWARDS**Prizes**

1975	Hebrew University-Hadassah Medical School	"Excellency in Anatomy"	\$2,000
1975-1980	Hebrew University-Hadassah Medical School	"Excellence in Studies". (Each year)	\$3,000
1988	Hebrew University-Hadassah Medical School	Faculty-Prize for Research "Preferential metabolism by (Sole and Goldberg prize): macrophages of conditioned rabbit hypercholesterolemic remnant lipoproteins."	\$3,000
1989		Award for Outstanding lecturer.	
1990	Hebrew University-Hadassah Medical School (Dr. M. Sherwood prize):	Faculty-Prize for Research "Cigarette smoking render LDL susceptible to peroxidative modification and enhanced metabolism by macrophages."	\$4,000
1995	Giovanni Lorenzini Medical Foundation	Young Investigator Award, Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter	\$2,000
1995	Sheba Medical Center Tel-Hashomer, Israel.	"El-Zohar" Research Prize	\$4,000

E. ACADEMIC & PROFESSIONAL AWARDS (cont.)**Prizes**

1996	Uchida International Award Japan Foundation of Cardiovascular Research	Young Investigator Award, Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter	¥1,000,000
------	--	---	------------

Fellowships

1979	Albert Einstein College of Medicine New York, NY, USA.	Fellowship Prize.	\$3,500
1991	Israel Medical Association.	Fellowship-Prize.	\$4,000
1992	The University of California San Francisco San Francisco, USA.	“Boehringer Ingelheim” Honorary Fellowship	\$25,000

Grants

1991	The Israel Academy of Sciences and Humanity	“Wolfson” grant	\$20,000
1992-1994	NIH	Fogarty International Fellowship Grant.	\$70,000
1995-1998	United State-Israel Binational Science Foundation.	Binational Grant “Overexpression of 15LO in Transgenic Mice”.	\$110,000
1995	Syntex Discovery Research Palo-Alto, California, USA.	Research Grant in Vascular Biology	\$10,000
1995-1998	The Ministry of Science and The Arts	Tissue Specific Gene Therapy to Neovascular Endothelial Cells	\$40,000
1996-1997	Israel Cancer Association	Tissue Specific Gene Therapy to Neovascular Tumoral Cells	\$25,000

E. ACADEMIC & PROFESSIONAL AWARDS (cont.)**Grants**

1996-2000	Mercator Genetics	The "Asthma-Gene" in the Jewish population in Israel	\$507,000
1997-1998	Tiber	"Overexpression of 15LO in Transgenic Mice".	\$3000
1998-2000	Recanati Medical Foundation	Long QT Syndrome: The molecular basis of a new mutation.	\$22,000
1998-1999	MSD Foundation Research Grant	Secondary Prevention Study ("HOLEM")	\$480,000
1998-1999	Gotvirt Diabetes Research Fund	Israel cohort of Glucose intolerance (Phase 3)	\$5,000
1999	Ministry of Health, Chief Scientists office, Jerusalem	Oral Tolerance in Atherosclerosis	נ"ש20,000
2000-2001	Recanati Medical Foundation	Tissue Specific Gene Therapy to Neovascular Tumoral Cells.	\$25,000
2000-2001	Israel Cancer Association	Using Preproendothelin promoter to direct pro-apoptotic genes to endothelial cells in tumor angiogenesis.	נ"ש65,000
1999-2002	BMS Genetic Research Grant	Genetics of COPD	\$320,000
2000-2003	Cardimmune	Immunomodulation and oral tolerance in atherosclerosis.	\$240,000
2001-2002	Olivia	The effect of fatty acids composition on atherogenesis.	\$150,000
2001-	Serono	Soluble LDL Receptor	\$96,000

E. ACADEMIC & PROFESSIONAL AWARDS (cont.)**Grants**

2002-	Nikken-Shohonsha	9-cis retinoic Acid-Lipid Metabolism & Atherogenesis.	\$305,000
2000-2002	Roche	Xenical in severe hypertriglyceridemic patients.	CHF131,200
2001-2002	קרן עזבונות	Using Preproendothelin promoter to direct pro-apoptotic genes to endothelial cells in tumor angiogenesis.	₪150,000

Academic Awards

1999-	Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel	Associate Professor in Internal Medicine
1995-1999	Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel	Senior lecturer in Internal Medicine
1990-1995	Hebrew University Hadassah Medical School, Jerusalem, Israel.	Lecturer in Internal Medicine
1987-1990	Hebrew University Hadassah Medical School, Jerusalem, Israel.	Instructor in Internal Medicine

F. MEMBERSHIP IN PROFESSIONAL SOCIETIES

<u>Since</u>	<u>Society</u>	<u>Country</u>
1981	Israel Medical Association.	Israel
1987	Israel Society for Research, prevention and Treatment of Atherosclerosis	
1989	International Atherosclerosis Society.	USA
1991	American Lung Association.	USA
1991	American Thoracic Society.	USA
1991	American Clinical of Chest Physicians.	USA
1992	American Heart Association.	USA
1994	Israel Society of Pulmonary Medicine.	Israel
1996	European Atherosclerosis Society	
1996	International Task Force for prevention and Treatment of Atherosclerosis	
1998	Israel Heart Society	Israel
1998	Israel Task Force for prevention and Treatment of Atherosclerosis	Israel
2000	Israel Society of Obesity	Israel

G. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

<u>Year</u>	<u>Name of Meeting</u>	<u>Location</u>
2002	Irish Angiology Symposium- Invited speaker	Belfast, Ireland
2002	International Symposium on Infection & Atherosclerosis Invited speaker	Washington DC, USA
2002	6 th International Dead sea symposium – Invited speaker	Tel-Aviv, Israel
2001	37 th EASD Annual Meeting – Invited speaker	Glasgow, Scotland
2001	International Diabetes and Atherosclerosis Symposium – Invited speaker	Troon, Scotland
2001	Orphan Nuclear Receptors	Sunnyvale, CA., USA
2001	American Diabetes Association – Invited speaker	Tempe, Arizona, USA
2001	EAS workshop on the Immune System & atherosclerosis - Chairman	Geneva, Switzerland
2001	The 7 th Annual meeting of the Society for Research, Prevention and Treatment of Atherosclerosis	Eilat, Israel
2000	XII th International Symposium on Atherosclerosis – Invited speaker	Stockholm, Sweden
2000	3 rd Annual Meeting of American Society of Gene Therapy	Colorado, USA
2000	2000 EAS workshop, Low HDL in Cardiovascular diseases	Istanbul, Turkey
1999	1999 NAASO Annual Meeting	Charleston, SC, USA
1999	Immunological Aspects on Cardiovascular Diseases – Invited speaker	Stockholm, Sweden
1999	46 th annual meeting of the Israel Heart Society	Tel-Aviv, Israel
1999	Gordon Research Conferences, Atherosclerosis	Boston, USA
1999	5 th Int. Symposium: Multiple risk factors in cardiovascular disease – Invited speaker	Venice, Italy
1999	2 nd International Congress of Autoimmunity Invited speaker	Tel Aviv, Israel
1999	71 th European Atherosclerosis society – Invited speaker	Athens, Greece
1999	71 th Scientific Sessions, American Heart Assoc.	Dallas, USA
1998	The Scientific Meeting of the Society for Research, Prevention & Treatment of Atherosclerosis.	Ashkelon, Israel
1998	70 th European Atherosclerosis society – Invited speaker	Geneva, Switzerland
1998	European Heart Society.	Vienna, Austria
1998	The Annual Meeting of the Society for Research, Prevention & Treatment of Atherosclerosis.	Eilat, Israel
1998	Keystone Symposia on Gene Therapy	Keystone, USA
1997	The 11 th International Atherosclerosis Society – Invited speaker	Paris, France
1997	70 th Scientific Sessions, American Heart Assoc.	Orlando, USA
1997	American Thoracic Society International conf.	SF, USA
1997	Keystone Symposia on Atherosclerosis	Keystone, USA

G. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS (cont.)

<u>Year</u>	<u>Name of Meeting</u>	<u>Location</u>
1996	International Task Force for prevention and Treatment of Atherosclerosis – Invited speaker	Berlin, Germany
1996	The Israel Society for Arteriosclerosis Research.	Jerusalem, Israel
1996	64th European Atherosclerosis society.	Florence, Italy
1996	The Annual Meeting of the Society for Research, Prevention & Treatment of Atherosclerosis.	Eilat, Israel
1995	The Israel Society of Pulmonary Medicine	Tel Aviv, Israel
1995	The Israel Society for Arteriosclerosis Research.	Tel-Aviv, Israel
1995	68th Scientific Sessio, American Heart Assoc.	Anahime, USA
1995	9th Inter. Symp; Drug Affecting Lipid Metabolism.	Huston, USA
1995	68th Scientific Sessions, American Heart Assoc.	Anaheim, USA
1995	64th European Atherosclerosis society – Invited speaker	Utrecht, Netherlands
1995	American Thoracic Society International conf.	Seattle, USA
1995	5th Rappaport Symposium on Modified Lipo-proteins & Antioxidant in Atherosclerosis.	Shavei-Zion, Israel
1995	FASEB Conference, Experimental Biology – Invited speaker	Atlanta, USA
1995	The Annual Meeting of the Society for Research, Prevention & Treatment of Atherosclerosis.	Eilat, Israel
1994	67th Scientific Sessions, American Heart Assoc.	Dallas, USA
1994	the 9th International Conference on Prostaglandins & Related Compounds.	Florence, Italy
1994	American Thoracic Society International conf.	Boston, USA
1994	The 5th UCSF Pulmonary Research Meeting.	Asilomar Ca., USA
1993	66th Scientific Sessions, American Heart Assoc.	Atlanta, USA
1993	American Thoracic Society International conf.	San Francisco, USA
1993	The 4th UCSF Pulmonary Research Meeting.	Asilomar Ca., USA
1993	The Annual AIDS Scientific Meeting.	San Francisco, USA
1992	American Thoracic Society International conf.	Orlando, USA
1991	The 9th international symposium on atherosclerosis.	Chicago, USA
1990	The Israel Society for Arteriosclerosis Research.	Tel-Aviv, Israel
1990	55th European Atherosclerosis Society.	Brugge, Germany

STUDENTS SUPERVISED BY CANDIDATE

G.1 M.D. STUDENTS

The Hebrew University Hadassah Medical School Jerusalem.

1990-1991 Peleg Ben Galim M.D.

Thesis: "Lipid peroxides in down's syndrome: A study related to the paucity of atherosclerosis in this condition".

Sackler School of Medicine Tel Aviv University

1998 Yoav Keidar M.D. Thesis

Thesis: "Effect of Colchicine on Atherosclerosis in LDL-Receptor deficient mice".

1998 Yaniv Sherer M.D. Thesis

Thesis: "Magnesium fortification of drinking water and atherosclerosis in LDL-receptor ko mice."

2001 Ayana Dvir M.D. Thesis

Thesis: "The effect of Omapatrilat on atherogenesis in a combined atherosclerosis – diabetes mouse model in LDL receptor deficient streptozotocin treated mice".

G.2 M.Sc. & Ph.D. STUDENTS

1995-2001 Nira Blum Ph.D.

Thesis: "Tissue Specific Gene Therapy to Neovascular Tumoral-Endothelial Cells".

1997-2000 Pnina Keren Ph.D.

Thesis: "Diabetes in Transgenic Mouse Model of Atherosclerosis".
Graduate Cum Laude

1997-1999 Einat Golan M.Sc.

Thesis: "Regulation of LDL-Receptor Expression in Lovastatin Resistant Cells".

1998- Yariv Gerber Ph.D.

Thesis: " Apo CII, CIII, TG & Atherosclerotic Cardiovascular Diseases"

1998- Ayelet Gonen M.Sc.

Thesis: " Adenoviral Gene Therapy to Neovascular Tumoral-Endothelial Cells"

1998- Grinberger Shoshi MD Ph.D.

Thesis: " Induction of Apoptosis in Endothelial Cells"

G.2 M.Sc. & Ph.D. STUDENTS (cont.)

- 1999-
Thesis: Keren Levanon MD/Ph.D.
"Adenoviral Gene Therapy for Induction of Angiogenesis and vessel maturation."
- 2001-
Thesis: Ayelet Gonen Ph.D.
"The effect of Allicin derivatives on atherosclerosis mode of actions."
- 2001-
Thesis: Israel Hodish MD Ph.D.
"Engineering of adeno-viral vector containing the HSV-TK gene under the control of murine pre-proendothelin promoter for the treatment of cancer".

G.3 Resident's basic science projects supervised by candidate

- 1999
Thesis: Arnon Afek Basic-science
"Anti-HSP65-antibodies and atherosclerosis in LDL-Receptor deficient mice".
- 1998
Thesis: Rafael Bitzur Basic science
"Induction of IDDM in Transgenic Mouse Model of Atherosclerosis".
- 1997
Thesis: Jakob George Basic-science
"Anti-phospholipids-antibodies and atherosclerosis in LDL-Receptor deficient mice".
- 1997
Thesis: Peer Dar Zitser Basic-science
"15 Lipxygenase overexpression reduces fertility in Tg mice".
- 1999
Thesis: Svetlana Poyarovski Basic-science
"חקר הגנטיקה של COPD בשושלת יוחסין מבודדת בישראל."
- 1999
Thesis: Eyal Leibovitz Basic-science
"The Association between the polymorphism of the human Paraoxonase gene with plasma Paraoxonase activity and coronary artery disease in Israeli Jewish population."

G.3 Resident's basic science projects supervised by candidate (cont.)

1999 <u>Thesis:</u>	Lea Hananashvili Basic-science "Efficacy of the combination of Fibrates and 9 cis Retinoic Acid on the lipid profile of human Apo A1 transgenic mice".
2000 <u>Thesis:</u>	Roy Ilan Basic-science "Amplification of gene expression in transfected cardiomyocytes by ultrasound."
2000 <u>Thesis:</u>	Levi Zohar Basic-science "The effect of the natural isomer mixture of β -carotene from the alga Dunaliella on the degree and extent of atherosclerosis in apo E deficient mice."
2000-2001 <u>Thesis:</u>	Swetlana Trastman Basic-science "The effect of the cytokine interferon- α on the degree of atherosclerosis in LDL receptor deficient mice".
2001 <u>Thesis:</u>	Afek Limor Basic-science "Oral Tolerance to ox-LDL in LDL-Receptor deficient mice."
2001 <u>Thesis:</u>	Vladimir Chesnin Basic-science "Plasma levels and distribution of CII and CIII apolipoproteins: Are they risk factors for Alzheimer's disease?"
1999-2000 <u>Thesis:</u>	Hagith Yonath Basic-science "Inter-individual variability in sensitivity to warfarin – nature or nurture?"
2001 <u>Thesis:</u>	Marunich Anastasya Basic-science "The effect of the natural isomer mixture of β -carotene from the alga Dunaliella on the degree and extent of atherosclerosis in apo E deficient mice."

TEACHING EXPERIENCE

Hebrew University Hadassah Medical School, 1988-1991.

Teaching activities before my departure to the USA.

- 1990 Coordinator of a course in internal medicine for 6th year medical students.
- 1990-1989 Coordinator of the course in cardiopulmonary resuscitation for 6th year medical students.
- 1988-1991 Coordinator of the course in internal medicine for Biotechnicians at the Hadassah College.
- 1989 Award for Outstanding lecturer at the Hebrew University Hadassah Medical School.
- 1988-1991 Teaching internal medicine to 4th year medical students.
- 1990-1991 Supervising an M.D. thesis work at the Hebrew University Hadassah Medical School. "Lipid peroxides in down's syndrome: A study related to the paucity of atherosclerosis in this condition."
- 1990-1991 Member in the Hebrew University Hadassah Medical School. Committee, interviewing candidates for medical school.
- 1990-1991 Teaching in the course of medicine to the new emigrants MDs from the USSR, at the Hebrew University Hadassah Medical School.
- 1991 Preparing the Boards in Internal Medicine for Medical Graduate at the Hebrew University Hadassah Medical School.

Sackler Faculty of Medicine, Tel Aviv University, 1995.

I returned to Israel from the USA in December 1994, since than I am involve in the following teaching activities.

- 1998- 2002 Member of the Medical School Teaching Committee (ועדת הוראה)
- 1998- 2001 Organizing the "Basic Science Correlate Course".
- 1998- 2000 Member of the Committee for Organizing the Clinical Studies Curriculum
- 1998- 2000 Member of the Committee for Organizing the Basic Studies Curriculum
- 1998- 1999 Head of the subcommittee for teaching facilities in the clinical years.
- 1997- 2002 Teaching in the PostGraduate School of Medicine; "Lipids and Lipoprotein Metabolism."
- 1995- 2002 Teaching in the course of Biochemistry for first and third year medical students; "Lipids and Lipoprotein Metabolism."
- 1995- 2002 Teaching fourth year medical students in the course of Internal Medicine; "Hyperlipidemia & Atherosclerosis."
- 1995- 2002 Teaching fourth year medical students (both the NY and the regular program) in the courses Pulmonary medicine.
- 1995- 2002 Teaching in the "Gene Therapy" course for M.Sc. & Ph.D. students.
- 1995- 2002 Seminars in gene therapy to physicians and researchers at Tel Hashomer.

LIST OF PUBLICATIONS

A. Book Written

1. Shoenfeld, Y., Harats, D., Wick, G.
Atherosclerosis and Autoimmunity.
Elsevier, 370pp, 2001.

B.1. Original Article

1. Published

1. Stein, Y., Halperin, G., Harats, D., Stein, O.
Metabolic fate and effect on cholesterol removal of liposomes prepared from 1,3-di-o-octadecenylglycero-2-phosphocholine studied in vivo and in vitro.
Biochim. Biophys. Acta 922: 191-198, 1987.
2. Harats, D., Stein, O., Schwartz, R., Berry, E. M., Stein, Y.
Preferential metabolism by macrophages of conditioned rabbit hypercholesterolemic remnant lipoproteins.
Biochim. Biophys. Acta 959: 127-133, 1988.
3. Stein, O., Oette, K., Harats, D., Halperin, G., Stein, Y.
Sphingomyelin liposomes with defined fatty acids: metabolism and effects on reverse cholesterol transport.
Biochim. Biophys. Acta 960: 322-333, 1988.
4. Stein, O., Harats, D., Schwartz, R., Berry, E. M., Stein, Y.
Modification of cellular fatty acid composition of Hep-G2 cells; lipoprotein cholesterol secretion and effect of antioxidants.
Biochim. Biophys. Acta 1033: 115-120, 1989.
5. Harats, D., Ben-Naim, M., Dabach, Y., Hollander, G., Stein, O., Stein, Y.
Cigarette smoking render LDL susceptible to peroxidative modification and enhanced metabolism by macrophages.
Atherosclerosis 79: 245-252, 1989.
6. Harats, D., Raz, I., Lebensart, P.
Ultrasonographic appearance of well-defined splenic space occupying lesions in Gauchers Disease.
Isr. J. Med. Sci. 26: 168-170, 1990.
7. Harats, D., Ben-Naim, M., Dabach, Y., Hollander, G., Havivi, E., Stein, O., Stein, Y.
Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking.
Atherosclerosis 85: 47-54, 1990.

B.1. Original Article (cont.)**1. Published (cont.)**

8. Berry, E. M., Eisenberg, S., Harats, D., Friedlander, Y., Norman, Y., Kaufmann, N., Stein, Y.

Effects of diets rich in monounsaturated fatty acids on plasma lipoproteins - The Jerusalem Nutrition Study: high MUFAs vs high PUFAs.

Am. J. Clin. Nutr. 53:899-907, 1991.

9. Harats, D., Dabach, Y., Hollander, G., Ben-Naim, M., Schwartz, R., Berry, E. M., Stein, O., Stein, Y.

Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins; attenuating effect of vitamin E.

Atherosclerosis. 90: 127-139, 1991.

10. Berry, E. M., Eisenberg, S., Friedlander, Y., Harats, D., Kaufmann, N., Norman, Y., Stein, Y.

Effects of diets rich in monounsaturated fatty acids on plasma lipoproteins - The Jerusalem Nutrition Study. II: Monounsaturated fatty acids vs carbohydrates.

Am. J. Clin. Nutr. 56(2): 394-403, 1992.

11. Beigel, Y., Brook, G., Eisenberg, S., Fainaru, MS., Harats, D., Levy, Y., Rubinstein, A., Skurnik, Y.

Efficacy and safety of Pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience.

Isr. J. Med. Sci. 29 (5): 272-277, 1993.

12. Harats, D., Mulkin, M.A., Sigal, E.

A possible role for 15-lipoxygenase in atherosclerosis.

Trends in Cardiovascular Medicine. 5(1): 29-36, 1995.

13. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Ackley, D., Cain, G., Kurihara, Y., Lawn, R., Sigal, E.

Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.

JCI. 95: 1335, 1995.

14. Berry, E. M., Eisenberg, S., Friedlander, Y., Harats, D., Kaufmann, N., Norman, Y., Stein, Y.

Effects of diets rich in monounsaturated fatty acids on plasma lipoproteins - The Jerusalem Nutrition Study. Monounsaturated vs. saturated fatty acids.

Nutrition, Metabolism and Cardiovascular Diseases. 5:55-62, 1995.

B.1. Original Article (cont.)**1. Published (cont.)**

15. George, J., Afek, A., Gillburd, B., Levy, Y., Blank, M., Kopolovic, J., Harats, D., Shoenfeld, Y.
Atherosclerosis in LDL-receptor Knockout mice is accelerated by immunization with anticardiolipin antibodies.
Lupus 6(9):723-729, 1997.
16. D. Harats., Chevion, S., Nahir, M., Norman, Y., Sagee, O., Berry, ME.
Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting high saturated fat diet: presumptive evidence for an interaction between vitamin C and E in vivo.
AJCN 67(2):240-245, 1998.
17. George, J., Afek, A., Gillburd, B., Levkovitz, H., Shaish, A., Goldberg, Y., Kopolovic, Y., Shoenfeld, Y., Harats, D.
Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis.
Atherosclerosis 138(1):147-152, 1998.
18. George, J., Afek, A., Gillburd, B., Blank, M. Levy, Y., Aron-Maor, A., Levkovitz, H., Shaish, A., Goldberg, I., Kopolovic, J., Harats, D., Shoenfeld, Y.
Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta 2 glycoprotein I.
Circulation (11):1108-1115, 1998.
19. George, J., Gilburd, B., Langevitz, P., Levy, Y., Nezlín, R., Harats, D., Shoenfeld, Y.
Beta 2 glycoprotein I containing immune-complexes in lupus patients: association with thrombocytopenia and lipoprotein (a) levels.
Lupus 8(2):116-120, 1999.
20. Afek, A., George, J., Shoenfeld, Y., Gillburd, B., Levi, Y., Shaish, A., Keren, P., Goldberg, I., Kopolovic, J., and Harats, D.
Enhancement of atherosclerosis in beta 2 glycoprotein I immunized apo-E deficient mice.
Pathobiology 67:19-25, 1999.
21. George, J., Shoenfeld, Y., Afek, A., Gillburd, B., Keren, P., Shaish, A., Kopolovitz, Y., Wick, G., and Harats, D.
"Enhanced fatty streak formation in C57BL/6 mice by immunization with heat-shock protein 65"
Arterioscler. Thromb. Vasc. Biol. 19(3):505-510, 1999.

B.1. Original Article (cont.)**1. Published (cont.)**

22. Shaish, A., George, J., Gillburd, B., Keren, P., Levkovitz, H., Harats, D.
Dietary B-carotene and alpha-tocopherol combination dose not inhibit atherogenesis in an
Apolipoprotein E-deficient mouse model.
Arterioscler. Thromb. Vasc. Biol. 19 (6):1470-1475, 1999.

23. George, J*., Harats, D*., Gillburd, B., Afek, A., Levy, Y., Shneiderman, J.,
Koplovic, J., Shoenfeld, Y.
Immunolocalization of beta 2 glycoprotein I (Apolipoprotein-H) to human atherosclerotic
plaques: Potential implication for lesion progression.
Circulation 4(17):2227-2230, 1999.

***Both are first authors**

24. George, J., Aron, A., Levi, Y., Ben-David, A., Hojnik, M., Renaudineau, Y., Zonana-
Nachach, A., Youinou, P., Harats, D., Shoenfeld, Y.
Anti-cardiolipin, anti-endothelial-cell and anti-malonyldialdehyde-LDL antibodies in
uremic patients undergoing hemodialysis: relationship with vascular access thrombosis
and thromboembolic events
Human Antibodies 9:125-131, 1999.

25. George, J., Harats, D., Gilburd, B., Levy, Y., Langevitz, P., Shoenfeld, Y.
Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of
humoral immunity.
Lupus 8(3):220-226, 1999.

26. Zurgil, N., Levy, Y., Deutsch, M., Gilburd, B., George, J., Harats, D., Kaufman, M.,
Shoenfeld, Y.
Reactivity of peripheral blood lymphocytes to oxLDL: A novel system to estimate
atherosclerosis employing the cellscan.
Clin Cardiol. 22(8):526-532, 1999.

27. George, J., Harats, D., Bakshi, E., Adler, Y., Levy, Y., Gilburd, B., Shoenfeld, Y.
Anti-oxidized-low density lipoprotein antibody determination as a predictor of restenosis
following percutaneous transluminal coronary angioplasty.
Immunol Lett. 68(2-3):263-266, 1999.

28. Y., Levy, George, J., Langevitz, P., Harats, D., Doolman, R., Sela BA,
Shoenfeld, Y.
Elevated Homocysteine levels in patients with Raynaud's syndrome.
J. of Rheumatol. 26(11):2383-2385, 1999.

B.1. Original Article (cont.)**1. Published (cont.)**

29. George, J., Shoenfeld, Y., Harats, D.

The involvement of β 2-glycoprotein I (β 2GPI) in human and murine atherosclerosis.

J.of Autoimmunity 13:57-60, 1999

30. Abramovitz, D., Sagui, G., Harats, D., Levkovitz, H., Mirelman, D., Miron, T., Eilat-Adar, S., Rabinkov, A., Wilchek, M., Eldar, M., Vered, Z.

Allicin induced decrease in formation of fatty streaks (atherosclerosis) in mice fed a cholesterol rich diet.

Coronary Artery Disease 10:515-519, 1999.

31. Adler, Y., George, J., Shoenfeld, Y., Fink, N., Herz, I., Mager, A., Assali, A., Harats, D., Sagie, A.

Association between Mitral annulus calcification and anti β 2-Glycoprotein I antibody levels.

J. of noninvasive card. 3:111-115, 1999.

32. George, J., Mulkins, M., Casey, S., Schatzman, R., Sigal, E., Harats, D.

The effects of n-6 polyunsaturated fatty acid supplementation on the lipid composition and atherogenesis in mouse models of atherosclerosis.

Atherosclerosis 150:285-293, 2000.

33. George J., Ahmed A., Patnaik M., Adler Y., Levy Y., Harats D., Gilburd B., Terryberry J., Qui Shen G., Sagie A., Herz I., Snow P., Brandt J., Peter J., Shoenfeld Y.

The prediction of coronary atherosclerosis employing artificial neural networks.

Clinical cardiology 23:453-456, 2000.

34. Sherer, Y., Shaish, A., Levkovitz, H., Keren, P., Janackovic, Z., Shoenfeld, Y., Harats, D.

Magnesium fortification of drinking water suppresses atherogenesis in male LDL-Receptor knockout mice

Pathobiology 67:207-213, 1999.

35. Knoblauch, H., Muller-Myhsok, B., Busjahn, A., Ben Avi, L., Bähring, S., Baron, H., Heath, SC., Uhlmann, R., Faulhaber, HD., Shpitzen, S., Aydin, A., Reshef, A., Rosenthal, M., Eliav, O., Muhl, A., Lowe, A., Schurr, D., Harats, D., Jeschke, E., Friedlander, Y., Schuster, H., Luft, FC., Leitersdorf, E.

A cholesterol-lowering gene maps to chromosome 13Q.

The American J. of Human Genetics 66(1):157-66, 2000.

B.1. Original Article (cont.)**1. Published (cont.)**

36. Afek, A., George, J., Gilburd, B., Rauova, L., Goldberg, I., Kopolovic, J., Harats, D., Shoenfeld, Y.

Immunization of low density lipoprotein receptor deficient (LDL-R) mice with Heat Shock Protein 65 (HSP-65) promotes early atherosclerosis.
J Autoimmun. 14(2):115-121, 2000.

37. Jacob George, Mary Mulkins, Aviv Shaish, Sharon Casey, Randall Schatzman, Elliott Sigal, Dror Harats.

IL-4 Deficiency does not Influence Fatty Streak Formation in C57BL/6 mice.
Atherosclerosis 153:403-411, 2000.

38. Dror Harats, Aviv Shaish, Jacob George, Mary Mulkins, Hiroki Kurihara, Hana Levkovitz and Elliott Sigal.

Overexpression of 15-Lipoxygenase in the Vascular Endothelium Accelerates Early Atherosclerosis in LDL Receptor-Deficient Mice.
Arteriosclerosis, Thrombosis and Vascular Biology 20(9):2100-5, 2000.

39. Pnina Keren, Jacob George, Aviv Shaish, Hana Levkovitz, Zora Janakovic, Arnon Afek, Iris Goldberg, Juri Kopolovic, Gad Keren, Dror Harats.

Effect of Hyperglycemia and Hyperlipidemia on Atherosclerosis in LDL-Receptor Deficient Mice: Establishment of a Combined Model and Association with HSP65 Immunity.
Diabetes (6):1064-9, 2000.

40. Sherer Y, Shoenfeld Y, Shaish A, Levkovitz H, Bitzur R, Harats D.

Suppression of atherogenesis in female LDL receptor knockout mice following magnesium fortification of drinking water-the importance of diet.
Pathobiology 68:93-98, 2000.

41. Halperin G, Elisaf M, Leitersdorf E and Harats D.

A new method for determination of serum cholestanol by high performance liquid chromatography with UV detection.
J.of Chromatography B. 742 (2): 345-352, 2000.

42. J. George, P-L. Meroni, B. Gilburd, E. Raschi, D. Harats and Y. Shoenfeld.

Anti-endothelial cell antibodies in patients with coronary atherosclerosis.
Immunol Lett. Jul 3;73(1):23-7, 2000.

B.1. Original Article (cont.)**1. Published (cont.)**

43. J. George, Y. Shoenfeld, B. Gilburd, A. Afek, A. Shaish and D. Harats.
Requisite role for IL-4 in the acceleration of fatty streaks induced by HSP 65 or
Mycobacterium Tuberculosis.
Circ Res. 86(12):1203-1210, 2000.

44. **J. George*** **D. Harats***, B. Gilburd, A. Afek, A. Shaish, J. Kopolovic, and Y.
Shoenfeld.
Adoptive transfer of $\beta 2$ glycoprotein I ($\beta 2$ GPI)-reactive lymphocytes enhances early
atherosclerosis in LDL receptor deficient mice.
Circulation 102:1822-1827, 2000.
***Both are first authors**

45. J. George, A. Afek, B. Gilburd, Y. Shoenfeld and D. Harats
Cellular and Humoral Immune response to HSP 65 are both involved in promoting fatty-
streak formation in LDL-receptor deficient mice.
JACC 38(3):900-905, 2001.

46. Y. Sherer, A. Tenenbaum, M. Blank, J. Shemesh, D. Harats, E.Z. Fisman, S.
Praprotnik, M. Motro, Y. Shoenfeld.
Autoantibodies to Oxidized Low-Density Lipoprotein in Coronary Artery Disease.
Amr J. Hypertension. 14:149-154, 2001.

47. Y. Sherer, J. Shemesh, A. Tenenbaum, M. Blank, D. Harats, E.Z. Fisman, S.
Praprotnik, M. Motro, Y. Shoenfeld
Coronary Calcium and Anti-Cardiolipin Antibody are elevated in patients with Typical
Chest pain.
Amr J. Cardiology 86(12):1306-1311, 2000.

48. T. Ravid, R. Doolman, R. Avner, D. Harats, J. Roitelman.
The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian
HMG-CoA reductase.
J Biol Chem. 275:35840-35847, 2000.

49. Pnina Keren, Jacob George, Gad Keren, Dror Harats.
Non-Obese Diabetic (NOD) mice exhibit an increased cellular immune response to
glycated-LDL but are resistant to high fat diet induced atherosclerosis
Atherosclerosis 157(2):285-292, 2001.

50. Tacke PJ, Teusink B, Jong MC, Harats D, Havekes LM, van Dijk KW, Hofker MH.
LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL
receptor transgenic and knockout mice.
J Lipid Res. 41(12):2055-2062, 2000.

B.1. Original Article (cont.)**1. Published (cont.)**

51. Y. Sharabi, E. Grossman, Y. Sherer, A. Shaish, H. Levkovitz, R. Bitzur, Harats D.
The effect of renin-angiotensin-axis inhibition on atherogenesis in LDL-receptor
deficient mice.
Pathobiology 68(6):270-274,2000.

52. Y. Sherer, A. Tenenbaum, S. Praprotnik, J. Shemesh, M. Blank, EZ. Fisman, D.
Harats J. George, Y. Levy, M. Motro, Y. Shoenfeld.
Coronary artery disease but not coronary calcification is associated with elevated levels
of cardiolipin beta-2-GPI and oxLDL antibodies.
Cardiology 95(1):20-24, 2001.

53. Yehuda Shoenfeld, Yaniv Sherer, Jacob George and Dror Harats.
Autoantibodies associated with atherosclerosis.
Ann Med. 32(1):37-40, 2000.

54. Y. Sherer, R. Bitzur, H. Cohen, A. Shaish, D. varon, Y. Shoenfeld, D. Harats.
Mechanisms of action of the anti-atherogenic effect of magnesium: Lessons from a
mouse model.
Magnesium Research 14(3):173-179, 2001.

55. N. Varda-Bloom, A. Shaish, A. Gonen, K. Levanon, S. Greenbereger, S. Ferber, H.
Levkovitz, A. Afek, Y. Kopolovitch, D. Harats.
Tissue-Specific Gene Therapy Directed to Tumor Angiogenesis.
Gene Therapy 8(11):819-827, 2001.

56. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., Roitelman
J., Harats D., Ezra D., Halkin H.
Inter-individual variability in sensitivity to warfarin – nature or nurture?
Clin. Pharmacol. Ther. 70(2):159-164, 2001.

57. J. George, A. Afek, A. Shaish, H. Levkovitz, N. Bloom, T. Cyrus, L. Zhao, C. D.
Funk, E. Sigal, D. Harats.
12/15-Lipoxygenase Gene Disruption Attenuates Atherogenesis in LDL-Receptor
Deficient Mice.
Circulation 104(14):1646-1650, 2001.

58. Y. Shoenfeld, Y. Sherer, D. Harats.
Atherosclerosis as an infectious, inflammatory and Autoimmune disease.
Trends Immunol. 22(6): 293-295, 2001.

B.1. Original Article (cont.)**1. Published (cont.)**

59. D. Harats, O. Yodfat, R. Doolman, S. Gavendo, D. Marko, A. Shaish, BA. Sela.
Homocysteine elevation with fibrates: is it a class effect?
IMAJ 3(2): 243-246, 2001.

60. PA. Gordon, J. George, MA. Khamashta, D. Harats, G. Hughes, Y. Shoenfeld.
Atherosclerosis and autoimmunity.
Lupus 10(4):249-252, 2001.

61. P. Dar, D. Strassburger, A. Shaish, H. Levkovitz, G. Halperin, D. Harats.
Reduced reproduction with increased abortion rate in transgenic mice that overexpress
15-lipoxygenase.
Gynecol Obstet Invest 52(1):18-21, 2001.

62. J. George, D. Harats, Y. Shoenfeld.
Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome.
Rheum Dis Clin north Am 27(3):603-610, 2001.

63. A. Afek, G. Keren, D. Harats, J. George.
Whole body hyperthermia accelerates atherogenesis in low-density lipoprotein receptor
deficient mice.
Exp Mol Pathol 71(1):63-72, 2001.

64. A. Shaish, G. Keren, P. Chouraqui, H. Levkovitz, D. Harats.
Imaging of aortic atherosclerotic lesions by ¹²⁵I-LDL, ¹²⁵I-Oxidized-LDL, ¹²⁵I-HDL and
¹²⁵I-BSA.
Pathobiology 69:225-229, 2001.

65. O. Shpilberg, I. Rabi, K. Schiller, R. Walden, D. Harats, K.S. Tyrrell, B. Coller, U.
Seligson.
Patients with Glanzmann thrombasthenia Lacking platelet glycoprotein α IIb/ β 3 and
(GPIIb/IIIa) and α V β 3 receptors are not protected from atherosclerosis.
Circulation 105:1044-1048, 2002.

66. Hofit Cohen, Yariv Sherer, Aviv Shaish, Yehuda Shoenfeld, Hana Levkovitz, Refael
Bizur, Dror Harats.
Atherogenesis inhibition induced by magnesium-chloride fortification of drinking water.
Biological Trace Element Research (In press).

67. Yariv Gerber, Uri Goldburt, Hofit Cohen, Dror Harats.
Association between serum apolipoprotein CII concentration and coronary heart disease.
Preventive Medicine 35:42-47, 2002.

64. E. Leibovitz, D. Harats, D. Gavish.
Efficacy of Atorvastatin in Treating High Risk Patients to Reach Low Density Lipoprotein-Cholesterol Goals: The Treat to Target (TTT-Israel) Study.
IMAJ 4(6): 407-410, 2002.
65. A. Adunsky, V. Chesnin, M. Davidson, Y. Gerber, D. Harats.
A cross-sectional study of lipids and ApoC levels in Alzheimer patients with and without cardiovascular disease.
J Gerontol A Biol Sci Med Sci. 57(11):M757-61, 2002.
66. D. Harats, N. Yacov, B. Gilburd, Y. Shoenfeld, J. George.
Oral Tolerance with Heat Shock Protein (HSP)-65 Attenuates Mycobacterium Tuberculosis Induced as Well as High Fat Diet Driven Atherosclerotic Lesions.
J Am Coll Cardiol. 2002 Oct 2;40(7):1333.
67. Shenhav S, Gemer O, Schneider R, Harats D, Segal S.
Severe hyperlipidemia-associated pregnancy: prevention in subsequent pregnancy by diet.
Acta Obstet Gynecol Scand. 81(8):788-90, 2002.
68. Z. Levy, A. shaish, N. yacov, H. levkovitz, S. trestman, Y. Gerber, H. Cohen, A. Dvir, R. Rhachmani, D. Harats.
Rosiglitazone (PPAR γ -AGONIST) Attenuates Atherogenesis With No Effect on Hyperglycemia in a Combined Diabetes-atherosclerosis mouse model.
Diabetes, obesity & Metabolism. (In-press).

B.2. Case Reports

1. Harats, D., Friedlander, M. ,Koplovic, Y. , Friedman, G.
Prolonged reversible acute renal failure in focal glomerulonephritis with severe nephrotic syndrome in an elderly patient.
Klin. Wochensch. 67(9): 502-505, 1989.
2. Harats, D. Manny, N., Raz, I.
Autoimmune hemolytic anemia in Gauchers Disease.
Klin. Wochensch. 68: 94-95, 1990.
3. D, Harats., Pauzner, R., Elstein, D., Mani, A., Klutstein, MW., Kramer, RM., Farfel, Z., Zimran, A.
Pulmonary Hypertension in two patients with Type I Gaucher disease while on alglucerase therapy.
Acta Haematol. 98(1):47-50, 1997.

B.3. Review Articles

1. Stein, Y., Harats, D., Stein, O.

Why is smoking a major risk factor for coronary heart disease in hyperlipidemic subjects.
Annals of the NY Academy of Sciences. 686: 66-69; discussion 69-71, 1993.

2. Harats, D.

הגנטיקה של היפרליפידמיה

The genetics of Hyperlipidemia.

Cardiology Update 10:27-32,1995.

3. George, J., Harats, D., Gillburd, B., Shoenfeld, Y.

Emerging Cross-Regulatory Roles of Immunity and Autoimmunity in Atherosclerosis.

Immunol Res 15(4):315-322, 1996.

4. Shoenfeld, Y., Harats, D., George, J.

Atherosclerosis and the antiphospholipid syndrome: A link unravelled?

Lupus 7(2):s140-s143, 1998.

5. Harats, D., George, J., Levy, Y., Khamashta, MA., Hughes, GRV., Shoenfeld, Y

Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus

Quart. J. Med. 92(1):57-59,1999.

6. Bakshi, E., George, J., and Harats, D.

Ox-LDL and atherosclerosis

Harefua 135: 459-463, 1998.

7. Harats, D., George, J., Shoenfeld, Y.

Atherosclerosis: An autoimmune mechanism unravelled.

Seminars in Immunol. (In-press).

8. George, J., Harats, D., Shoenfeld, Y.

Inflammatory and immune aspects of atherosclerosis.

IMAJ. 1:112-116, 1999.

9. George, J., Harats, D., Shoenfeld, Y.

Autoimmunity in atherosclerosis. The Role of Autoantigens.

Clinical rev. in Allergy & Immunology 18:73-86, 2000.

10. Harats, D., Rubinstein, A.

Joint recommendations of Israel medical societies for prevention of coronary heart diseases and atherosclerosis.

Harefua 138: 66-74, 2000.

B.3. Review Articles (Cont.)

11. George, J., Afec, A., Gilbrud, B., Harats, D., Shoenfeld, Y.
Autoimmunity in atherosclerosis: lessons from experimental models.
Lupus 9:223-227, 2000.
12. Y. Shoenfeld, D. Harats and J. George
HSP 60/65, β 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis
J Autoimmun. (2):199-202, 2000.
13. Yehuda Shoenfeld, Yaniv Sherer, Yaakov George, Dror Harats.
 β 2-glycoprotein-I in Human and Murine Atherosclerosis.
IMAJ. 3:85-7, 2001.
14. Harats D., George J.
Beta(2)-glycoprotein 1 and atherosclerosis.
Current Opinion in Lipidology 12(5):543-546, 2001.

B.4. Chapters in Books

1. Goldkorn, T., George, J., Lavrentiadou, T., Ravid, T., Tsaba, Y., Shoenfeld, Y., Harats, D.
Ceramide pathway and apoptosis in autoimmunity and atherosclerosis.
In: Atherosclerosis and Autoimmunity; Elsevier, 73-86, 2001.
2. Shoenfeld, Y., George, J., Sherer, Y., Harats, D.
Atherosclerosis: Evidence for the role of autoimmunity.
In: Atherosclerosis and Autoimmunity; Elsevier, 139-142, 2001.
3. Shere, Y., Blank, M., Varrala, O., Shaish, A., Shoenfeld, Y., Harats, D.
Anti-prothrombin antibodies in thrombosis and atherosclerosis.
In: Atherosclerosis and Autoimmunity; Elsevier, 185-190, 2001.
4. Harats, D., Cohen, H.
טרשת העורקים - הבנה ביולוגית חדשה, מערכת החיסון וסוכרת.
Atherosclerosis – the immune system and diabetes
Diabetes Mellitus in the 3rd millennium, 117-130, 2001
סוכרת באלף השלישי, האגודה הישראלית לסוכרת, 2001, 117-130

D.1. Invited papers in scientific meeting

1. Stein, O., Harats, D., Stein, Y.
Lipoproteins, smooth muscle cells and macrophages.
In: Proceedings of 8th intl. Symposium Atherosclerosis, Rome, Atherosclerosis VIII, ed. G. Crepaldi, Excerpta Medica: 81-84, 1988.
2. Stein, Y., Halperin, G., Harats, D., Stein, O.
Metabolic fate and effect on cholesterol removal of liposomes prepared from 1,3-di-o-octadecenylglycero-2-phosphocholine studied in vivo and in vitro.
Oncology Overview. 18: October 1989.
3. Sigal, E., Kurihara, H., Belloni, P., Cain, G., Lawn, R., Harats, D.,
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.
In the proceedings of the 64th European Atherosclerosis Society, Utrecht, Netherlands, S41, 1995.
4. Harats, D., Kurihara, H., Levkovitz, H., Shaish, A., Sigal, E.
15-Lipoxygenase overexpression induces atherosclerosis in LDL -receptor deficient mice.
Circulation (134) 279, 1997.
5. Harats, D.
The immune system in atherogenesis.
In the proceedings of the 4th Annual Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, Israel, 1998.
6. Harats, D., George, J., Afek, A., Gillburd, B., Levkovitz, H., Shaish, A., Kopolovitz, Y., Wick, G., Shoenfeld, Y.
Immunomodulation of atherogenesis.
In the proceedings of the 70th EAS, Geneva, Switzerland, 1998.
7. Harats, D., George, J., Gillburd, B., Afek, A., Shaish, A., Shoenfeld, Y.
Beta 2 glycoprotein I (Apolipoprotein-H) as an influential determinant in atherosclerosis.
In the proceedings of the 71st ESA congress, Athens, Greece, May 1999.
8. D. Harats, J. George, B. Gilburd, A. Afek, A. Shaish, Y. Shaish.
Adoptive transfer of β 2-glycoprotein I reactive lymphocyte enhances atherosclerosis in LDL receptor deficient mice In the proceedings of the 12th ISA, Stockholm, Sweden, 2000.
9. D. Harats.
The Immune system in Atherosclerosis. In the proceedings of the 37th EASD, Glasgow, Scotland, 2001.

D.2. Papers presented at scientific meetings

1. Harats, D., Stein, O., Stein, Y.
Cigarette smoking render LDL susceptible to peroxidative modification.
The Israel Society for Arteriosclerosis Research, Tel-Aviv, March 1990.
2. Stein, Y., Berry, E. M., Eisenberg, S., Harats, D., Friedlander, Y., Norman, Y., Kaufmann, N.
Effect of dietary mono-vs. polyunsaturated fatty acids on plasma lipoproteins in a free living population.
The 55th Annual Meeting of the European Atherosclerosis Society, Brugge, May 1990.
3. Eisenberg, S., Berry, E. M., Kaufmann, N., Harats, D., Friedlander, Y., Stein, Y.
The effect of dietary substitution of monounsaturated fatty acids (MFA) with carbohydrates (CHO) as lipoprotein levels, structure and function in a free living population.
The 63rd Scientific Sessions, American Heart Assoc., New Orleans, USA, Nov. 1993.
4. Beigel, Y., Levy, Y., Rubinstein, A., Skurnik, Y., Harats, D., Eisenberg, S., Brook, G., Fainaru, M.
Pravastatin therapy in Israel: Efficacy and safety in moderate hypercholesterolemic patients.
The 9th international symposium on atherosclerosis, Chicago, October 1991.
5. Berry, E. M., Eisenberg, S., Harats, D., Friedlander, Y., Kaufmann, N., Stein, Y.
The effects of dietary oleic acid on plasma lipids and their tendency to peroxidation.
The 9th international symposium on atherosclerosis, Chicago, October 1991.
6. Harats, D., Dabach, Y., Hollander, G., Ben-Naim, M., Schwartz, R., Berry, E. M., Stein, O., Stein, Y.
Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins; attenuating effect of vitamin E
The 9th international symposium on atherosclerosis, Chicago, October 1991.
7. Harats, D., Sigal, E.
Directing genes expression to the vascular wall and the airway epithelium in transgenic mice.
The 4th Pulmonary Research Scientific Meeting, Asilomar Ca. September, 1993.
8. Staler, F., Golden, J., Stansel, J., Harats, D., Montgomery, A.B., Walser, J.
Aerosolized recombinant human interferon gamma as adjuvant therapy for Pneumocystis Carinii Pneumonia in patients with AIDS.
The Annual AIDS Scientific Meeting. San Francisco, Ca. October, 1993.

D.2. Papers presented at scientific meetings (cont.)

9. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Ackley, D., Cain, G., Kurihara, Y., Lawn, R., Sigal, E.

Using transgenic mice to investigate *in vivo* biology of lipoxygenases.

The 9th International Conference on Prostaglandins & Related Compounds, Florence, June, 1994.

10. Harats, D., Sigal, E.

Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter

The 5th Pulmonary Research Scientific Meeting, Asilomar Ca. September, 1994.

11. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Cain, G., Kurihara, Y., Lawn, R., Sigal, E.

Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter

The 67th Scientific Sessions, American Heart Assoc., Dallas, USA, Nov. 1994.

12. Sigal, E., Kurihara, H., Belloni, P., Cain, G., Lawn, R., Harats, D.

Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.

FASEB Conference, Experimental Biology, Atlanta, USA April 1995.

13. Sigal, E., Kurihara, H., Belloni, P., Cain, G., Lawn, R., Harats, D.,

Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.

64th European Atherosclerosis Society, Utrecht, Netherlands, June, 1995.

14. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Cain, G., Kurihara, Y., Lawn, R., Sigal, E.

Taexpression to the vascular wall and the airway epithelium in transgenic mice using the murine preproendothelin-1 promoter.

The American Thoracic Society International conf., Seattle, USA, May 1995.

15. Harats, D., Tomlanovich, SJ, Conte, Jr JE, Golden, JA.

Aerosolized pentamidine prophylaxis for *Pneumocystis Carinii Pneumonia* in solid organ transplantation: Preliminary observation.

The 35th ICAAC, September 1995.

16. Harats, D., Kurihara, H., Lawn, R., Sigal, E.

Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.

The 12th Inter. Symp. on Drug Affecting Lipid Metabolism, Houston, Texas, USA. November, 1995.

D.2. Papers presented at scientific meetings (cont.)**17. Harats, D., Sigal, E.**

Targeting gene expression to the vascular wall in transgenic mice the murine prepromoter.

The Israel Society for Arteriosclerosis Research., Tel Aviv, Israel, December 1995.

18. Harats, D.,

Targeting gene expression to the airway epithelium and the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.

The annual meeting of the Israel Society of Pulmonary diseases, Tel Aviv, Israel, December 1995.

19. Harats, D., Kurihara, H., Levkovitz., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL deficient mice.

The 66th Annual Meeting of the European Atherosclerosis Society, Florence, Italy July 1996.

20. Harats, D.,

15-Lipoxygenase overexpression induces atherosclerosis in LDL deficient mice.

The Israel Society for Arteriosclerosis Research. Jerusalem, Israel, December 1996.

21. Harats, D., Kurihara, H., Levkovitz., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL deficient mice.

Keystone Symposia on Atherosclerosis, Keystone, USA 1997.

22. Harats, D., Kurihara, H., Sigal, E.

Targeting gene expression to the airway epithelium and the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.

International congress on cilia mucus & mucociliary interactions, Jerusalem, Israel, February 1997.

23. Harats, D., George, J., Afec, A., Gillburd, B., Levkovitz, H., Shaiah, A., Goldberg, I., Kopolovitz, Y., Shoenfeld, Y.

Hyperimmunization of chow fed apo-E deficient mice with homologous oxidized Low Density Lipoprotein suppresses early atherogenesis.

XI I.A.S, Paris France 1997

24. Harats, D., Kurihara, H., Levkovitz, H., Shaiah, A., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL -receptor deficient mice.

XI I.A.S, Paris France 1997

D.2. Papers presented at scientific meetings (cont.)

25. Harats, D., George, J., Afec, A., Gillburd, B., Blank, M., Goldberg, I., Kopolovitz, Y., Wick, G., Shoenfeld, Y.

Accelerated Early Atherogenesis in C57BL/6J Mice Immunized With Mycobacterium Tuberculosis. XI I.A.S, Paris France 1997

26. Shaish, A., George, J., Afec, A., Gillburd, B., Kopolovitz, Y., Shoenfeld, Y., Harats, D.

Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta 2 glycoprotein I.

XI I.A.S, Paris France 1997

27. Harats, D., Kurihara, H., Shaish, A., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL -receptor deficient mice.

70th Scientific Sessions, American Heart Assoc. Orlando, USA 1997

28. Harats, D., Shaish, A., George, J., Afec, A., Gillburd, B., Kopolovitz, Y., Shoenfeld, Y.

Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta 2 glycoprotein I.

70th Scientific Sessions, American Heart Assoc. Orlando, USA 1997

29. Ehrenfeld, M., Harats, D.

Serum lipoprotein(a) level in patients with systemic lupus erythematosus.

5th International Conference on SLE, Cancun, Mexico 1998

30. Harats, D., Shaiah, A., Levkovitz., Sigal, E., Bloom, VN.

Tissue specific gene therapy to the vascular wall.

Keystone Symposia on Gene-Therapy Keystone, USA 1998.

31. Harats, D.

The immune system in atherogenesis.

The 4th Annual Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, Israel, 1998.

32. Harats, D., George, J., Afek, A., Gillburd, B., Levkovitz, H., Shaish, A., Kopolovitz, Y., Wick, G., Shoenfeld, Y.

Immunomodulation of atherogenesis.

70th European Atherosclerosis society, Geneva, Switzerland, 1998.

33. Shaish, A., Levkovitz, H., George, J., Gillburd, B., Keren, P., Harats, D.

Antioxidant vitamins do not inhibit atherogenesis in an Apolipoprotein E-deficient mouse model.

70th European Atherosclerosis society, Geneva, Switzerland, 1998.

D.2. Papers presented at scientific meetings (cont.)

34. George, J., Shoenfeld, Y., Afek, A., Gillburd, B., Keren, P., Shaish, A., Kopolovitz, Y., Wick, G., and Harats, D.

"Enhanced fatty streak formation in C57BL/6 mice by immunization with heat-shock protein 65"

70th European Atherosclerosis society, Geneva, Switzerland, 1998.

35. Bloom, VN., Shaiah, A., Levkovitz., Sigal, E., Harats, D.

Tissue specific gene therapy to the vascular wall.

The Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

36. George, J., Shoenfeld, Y., Afek, A., Gillburd, B., Keren, P., Shaish, A., Kopolovitz, Y., Wick, G., and Harats, D.

"Enhanced fatty streak formation in C57BL/6 mice by immunization with heat-shock protein 65"

The Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

37. Afek, A., George, J., Gillburd, B., Keren, P., Goldberg, I., Kopolovic, J., Shoenfeld, Y., Harats, D.

Enhancement of atherosclerosis in apo-E deficient mice immunized with beta 2 glycoprotein I.

The Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

38. Shaish, A., George, J., Gillburd, B., Keren, P., Levkovitz, H., Harats, D.

Dietary B-carotene and alpha-tocopherol combination dose not inhibit atherogenesis in an Apolipoprotein E-deficient mouse model.

The Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

39. George, J., Harats, D., Afek, A., Gillburd, B., Shaish, A., Shoenfeld, Y.

The Role of Heat Shock Protein 65 (HSP) in Murine Atherosclerosis.

2nd International Congress of Autoimmunity, Tel Aviv, Israel, March 1999.

40. Harats, D., George, J., Gillburd, B., Afek, A., Shaish, A., Shoenfeld, Y.

β 2-Glycoprotein I (Apolipoprotein-H) as an Influential Determinant in Atherosclerosis.

2nd International Congress of Autoimmunity, Tel Aviv, Israel, March 1999.

D.2. Papers presented at scientific meetings (cont.)

41. Zurgil, N., Levy, Y., Deutsch, M., Gillburd, B., George, J., Harats, D., Kaufman, M., Shoenfeld, Y.

Reactivity of Peripheral Blood Lymphocytes (PBL) to oxLDL: A Novel System to Estimate Atherosclerosis Employing The Cellscan.

2nd International Congress of Autoimmunity, Tel Aviv, Israel, March 1999.

42. Harats, D., George, J., Afek, A., Gillburd, B., Shoenfeld, Y.

Administration of beta 2 glycoprotein I reduces atherogenesis in LDL-receptor-deficient mice.

5th Int. Symposium: Multiple risk factors in cardiovascular disease, Venice, Italy, October 1999.

43. Leibovitz, E., Gavish, D., Roitelman, Y., Shaish, A., Harats, D.,

The association of GLN-ARG 192 and MET-LEU 54 polymorphism of human paroxonase (PON1) gene with coronary artery disease in Israeli Jewish population.

5th Int. Symposium: Multiple risk factors in cardiovascular disease, Venice, Italy, October 1999.

44. Sherer, Y., Shaish, A., Levkovitz, H., Keren, P., Janackovic, Z., Shoenfeld, Y., Harats, D.

Magnesium fortification of drinking water suppresses atherogenesis in male LDL-Receptor knockout mice

46th annual meeting of the Israel Heart Society, Tel-Aviv, Israel, April 1999.

45. Keren, P., Shaish, A., Levkovitz, H., Gilbrud, B., Janakovic, Z., Shoenfeld, Y., Harats, D.

Combined hyperlipidemic hyperglycemic model of Atherosclerosis in Apo-E Deficient Mice:

46th annual meeting of the Israel Heart Society, Tel-Aviv, Israel, April 1999.

46. Shaish, A., Sherer, Y., Levkovitz, H., Shoenfeld, Y., Harats, D.

Magnesium fortification of drinking water suppresses atherogenesis in male LDL-Receptor knockout mice

71st ESA congress, Athens, Greece, May 1999.

47. Keren, P., George, J., Shaish, A., Levkovitz, H., Gilbrud, B., Janakovic, Z., Keren, G., Shoenfeld, Y., Harats, D.

Combined hyperlipidemic hyperglycemic model of Atherosclerosis in Apo-E Deficient Mice:

71st ESA congress, Athens, Greece, May 1999.

D.2. Papers presented at scientific meetings (cont.)

48. George, J., Harats, D., Gillburd, B., Afek, A., Levy, Y., Shaish, A., Barshak, I., Shneiderman, J., Kopolovic, J., Shoenfeld, Y.
Immunolocalization of beta 2 glycoprotein I (Apolipoprotein-H) to human atherosclerotic plaques: Potential implication for lesion progression.
71st ESA congress, Athens, Greece, May 1999.
49. Harats, D., George, J., Gillburd, B., Afek, A., Shaish, A., Shoenfeld, Y.
Beta 2 glycoprotein I (Apolipoprotein-H) as an influential determinant in atherosclerosis.
71st ESA congress, Athens, Greece, May 1999.
50. N. Varda-bloom, A. Shaish, A. Gonen, S. Ferber, H. Levkovitz, D. Harats.
Vascular Specific Gene Therapy to Tumor Veovascularization.
3rd Annual meeting, American society of gene Therapy, Denver, Colorado, June 2000.
51. P. Keren, A. Shaish, J. George, D. Harats
The effect of β -carotene and α -tocopherol supplementation on accelerated atherosclerosis in diabetic apoE deficient mice
12th ISA, Stockholm, Sweden, Vol 151(1), Page 12, 2000.
52. N. Varda-bloom, A. Shaish, A. Gonen, H. Levkovits, D. Harats.
The PPE1 promoter as a tool for specific gene therapy to angiogenic vascular endothelial cells
12th ISA, Stockholm, Sweden, Vol 151(1), Page 101, 2000.
53. D. Harats, J. George, B. Gilburd, A. Afek, A. Shaish, Y. Shoenfeld.
Adoptive transfer of β 2-glycoprotein I reactive lymphocyte enhances atherosclerosis in LDL receptor deficient mice
12th ISA, Stockholm, Sweden, Vol 151(1), Page 166, 2000.
54. A. Afek, J. George, Y. Shoenfeld, B. Gilburd, D. Harats.
Cellular humoral immune responses to HSP 65 are both involved in promoting fatty streak formation in LDL -receptor deficient mice
12th ISA, Stockholm, Sweden, Vol 151(1), Page 189, 2000.
55. A. Shaish, D. Mirelman, D. Abramovitz, T. Miron, A. Rabinkov, M. Wilchek, M. Eldar, Z. Vered, H. Levkovitz, D. Harats
12th ISA, Stockholm, Sweden, Vol 151(1), Page 257, 2000.
56. J. George, Y. Shoenfeld, B. Gilburd, A. Afek, A. Shaish, D. Harats
A requisite role for IL-4 in the acceleration of fatty streaks induced by HSP65 or mycobacterium tuberculosis
12th ISA, Stockholm, Sweden, Vol 151(1), Page 190, 2000.

D.2. Papers presented at scientific meetings (cont.)

57. T. Ravid, R. Doolman, R. Avner, M. Fainaro, D. Harats, J. Roitelman.
The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian HMG-CoA reductase.

The 7th Annual meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, Israel, May 2001.

58. A. Afek, G. Keren, D. Harats, J. George

Whole body hyperthermia accelerates atherogenesis in low density lipoprotein receptor deficient mice.

The 7th Annual meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, Israel, May 2001.

59. Z. Levy, A. Shaish, N. Yacov, H. Levkovitz, S. Trestman, Y. Gerber, H. Cohen, R. Rhachmani, D. Harats

Rosiglitazone attenuate atherogenesis with no effect on hyperglycemia in a combined diabetes-atherosclerosis mouse model.

The 7th Annual meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, Israel, May 2001.

60. H. Cohen, Y. Sherer, A. Shaish, H. Levkovitz, R. Bitzur, Y. Shoenfeld, D. Harats
Rosiglitazone attenuate atherogenesis with no effect on hyperglycemia in a combined diabetes-atherosclerosis mouse model.

The 7th Annual meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, Israel, May 2001.

61. D. Harats, J. George, Y. Shoenfeld.

Autoantigens in Atherogenesis

The EAS workshop on the Immune System & atherosclerosis. Geneva, Switzerland March 2001.

62. D. Harats.

The Immune system in Atherosclerosis.

The 37th Annual meeting of the EASD, Glasgow, Scotland, September 2001.

63. D. Harats.

The Immune system, Atherosclerosis and Diabetes.

The International Diabetes and Atherosclerosis Symp. Troon, Scotland, September 2001.

64. D. Harats.

The Immune system, Atherosclerosis and Diabetes.

The American Diabetes Association Workshop, Tempe, Arizona, USA, September 2001.

65. D. Harats. The immune system in cardiovascular disease.

The 6th International Dead sea symposium. Tel-Aviv, Israel, March 2002

D.3. Abstracts and Proceedings.

1. Published

1. Stein, Y., Halperin, G., Harats, D., Stein, O.
Metabolic fate and effect on cholesterol removal of liposomes prepared from 1,3-di-o-octadecenylglycero-2-phosphocholine studied in vivo and in vitro.
Oncology Overview. 18: October 1989.
2. Stein, Y., Berry, E. M., Eisenberg, S., Harats, D., Friedlander, Y., Norman, Y., Kaufmann, N.
Effect of dietary mono-vs. polyunsaturated fatty acids on plasma lipoproteins in a free living population.
In: Proceedings of the 55th Annual European Atherosclerosis Society Meeting, May 1990.
3. Eisenberg, S., Berry, E. M., Kaufmann, N., Harats, D., Friedlander, Y., Stein, Y.
The effect of dietary substitution of monounsaturated fatty acids (MFA) with carbohydrates (CHO) as lipoprotein levels, structure and function in a free living population.
Circulation , Supplement III. 82:4, 474, 1990.
4. Beigel, Y., Levy, Y., Rubinstein, A., Skurnik, Y., Harats, D., Eisenberg, S., Brook, G., Fainaru, M.
Pravastatin therapy in Israel: Efficacy and safety in moderate hypercholesterolemic patients.
In: Proceedings of the 9th international symposium on atherosclerosis, 48 October, 1991.
5. Berry, E. M., Eisenberg, S., Harats, D., Friedlander, Y., Kaufmann, N., Stein, Y.
The effects of dietary oleic acid on plasma lipids and their tendency to peroxidation.
In: Proceedings of the 9th international symposium on atherosclerosis, 92 October, 1991.
6. Harats, D., Dabach, Y., Hollander, G., Ben-Naim, M., Schwartz, R., Berry, E. M., Stein, O., Stein, Y.
Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins; attenuating effect of vitamin E
In: Proceedings of the 9th international symposium on atherosclerosis, 144 October, 1991.
7. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Ackley, D., Cain, G., Kurihara, Y., Lawn, R., Sigal, E.
Using transgenic mice to investigate *in vivo* biology of lipoxygenases.
In: Proceedings of the 9th International Conference on Prostaglandins & Related Compounds, 67 June, 1994.

D.3. Abstracts and Proceedings. (cont.)

8. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Cain, G., Kurihara, Y., Lawn, R., Sigal, E. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter
Circulation 90 (4) Part 2: I-517, 1994.

9. Sigal, E, Kurihara, H., Belloni, P., Cain, G., Lawn, R., Harats, D.
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-promoter.
FASEB, April 1995, IIIA856.

10. Harats, D., Kurihara, H., Belloni, P., Oakley, H., Ziober, A., Cain, G., Kurihara, Y., Lawn, R., Sigal, E.
Targeting gene expression to the vascular wall and the airway epithelium in transgenic mice using the murine preproendothelin-1 promoter.
Am. Rev. Resp. Dis. 151:4 A 672. 1995.

11. Harats, D., Kurihara, H., Belloni, P., Lawn, R., Sigal, E.
Using the murine preproendothelin-1 promoter to target gene expression to the vascular wall.
Atherosclerosis, 115/suppl S41, June, 1995.

12. Harats, D., Tomlanovich, SJ, Conte, Jr JE, Golden, JA.
Aerosolized pentamidine prophylaxis for *Pneumocystis Carinii Pneumonia* in solid organ transplantation: Preliminary observation.
In: Proceedings of The 35th ICAAC, (331) September 1995.

13. Sigal, E., Kurihara, H., Belloni, P., Cain, G., Lawn, R., Harats, D.,
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.
In the proceedings of the 64th European Atherosclerosis Society, Utrecht, Netherlands, S41, 1995.

14. Harats, D., Kurihara, H., Lawn, R., Sigal, E.
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.
In: Proceedings of The 12th Inter. Symp. on Drug Affecting Lipid Metabolism, 67; 1995.

15. Harats, D., Sigal, E.
Targeting gene expression to the vascular wall in transgenic mice the murine prepromoter.
In: Proceedings of The Israel Society for Arteriosclerosis Research. Tel Aviv, Israel, December 1995.

D.3. Abstracts and Proceedings. (cont.)

16. Harats, D., Kurihara, H., Levkovitz., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL deficient mice.

The 66th Annual Meeting of the European Atherosclerosis Society, Florence, Italy
Atherosclerosis, July 1996.

17. Harats, D.

15-Lipoxygenase overexpression induces atherosclerosis in LDL deficient mice.

In: Proceedings of The Israel Society for Arteriosclerosis Research. Jerusalem, Israel,
December 1996.

18. Harats, D., Kurihara, H., Levkovitz., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL deficient mice.

In: Proceedings of The Keystone Symposia on Atherosclerosis, 29, 1997.

19. Harats, D., George, J., Afec, A., Gillburd, B., Levkovitz, H., Shaiah, A., Goldberg, I., Kopolovitz, Y., Shoenfeld, Y.

Hyperimmunization of chow fed ApoE deficient mice with homologous oxidized Low Density Lipoprotein suppresses early atherogenesis.

Circulation (134) 18, 1997

20. Harats, D., George, J., Afec, A., Gillburd, B., Blank, M., Goldberg, I., Kopolovitz, Y., Wick, G., Shoenfeld, Y.

Accelerated Early Atherogenesis in C57BL/6J Mice Immunized With Mycobacterium Tuberculosis.

Circulation (134) 34, 1997.

21. Harats, D., Kurihara, H., Levkovitz, H., Shaish, A., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL -receptor deficient mice.

Circulation (134) 279, 1997.

22. Harats, D., Shaish, A., George, J., Afec, A., Gillburd, B., Kopolovitz, Y., Shoenfeld, Y.

Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta 2 GPI.

Circulation (134) 40-39, 1997.

23. Harats, D., Kurihara, H., Shaish, A., Sigal, E.

15-Lipoxygenase overexpression induces atherosclerosis in LDL -receptor deficient mice.

Circulation, (96) 8: I 167, 1997.

D.3. Abstracts and Proceedings. (cont.)

24. Harats, D., Shaish, A., George, J., Afec, A., Gillburd, B., Kopolovitz, Y., Shoenfeld, Y.

Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta 2 glycoprotein I.

Circulation, (96) 8: 1110, 1997.

25. Ehrenfeld, M., Harats, D.

Serum lipoprotein(a) level in patients with systemic lupus erythematosus.

Lupus:7 sup 1,63,1998.

26. Harats, D., Shaiah, A., Levkovitz., Sigal, E., Bloom, VN.

Tissue specific gene therapy to the vascular wall.

In the proceedings of the Keystone Symposia on Gene-Therapy Keystone, USA 1998.

27. Harats, D., George, J., Afek, A., Gillburd, B., Levkovitz, H., Shaish, A., Kopolovitz, Y., Wick, G., Shoenfeld, Y.

Immunomodulation of atherogenesis.

In the proceedings of the 70th European Atherosclerosis society, Geneva, Switzerland, 61, 1998.

28. Shaish, A., Levkovitz, H., George, J., Gillburd, B., Keren, P., Harats, D.

Antioxidant vitamins do not inhibit atherogenesis in an Apolipoprotein E-deficient mouse model.

In the proceedings of the 70th European Atherosclerosis society, Geneva, Switzerland, 34, 1998.

29. George, J., Shoenfeld, Y., Afek, A., Gillburd, B., Keren, P., Shaish, A., Kopolovitz, Y., Wick, G., and Harats, D.

“Enhanced fatty streak formation in C57BL/6 mice by immunization with heat-shock protein 65”

In the proceedings of the 70th European Atherosclerosis society, Geneva, Switzerland, 131, 1998.

30. Bloom, VN., Shaiah, A., Levkovitz., Sigal, E., Harats, D.

Tissue specific gene therapy to the vascular wall.

In the proceedings of the Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

D.3. Abstracts and Proceedings. (cont.)

31. George, J., Shoenfeld, Y., Afek, A., Gillburd, B., Keren, P., Shaish, A., Kopolovitz, Y., Wick, G., and Harats, D.

"Enhanced fatty streak formation in C57BL/6 mice by immunization with heat-shock protein 65"

In the proceedings of the Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

32. Afek, A., George, J., Gillburd, B., Keren, P., Goldberg, I., Kopolovic, J., Shoenfeld, Y., Harats, D.

Enhancement of atherosclerosis in apo-E deficient mice immunized with beta 2 glycoprotein I.

In the proceedings of the Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

33. Shaish, A., George, J., Gillburd, B., Keren, P., Levkovitz, H., Harats, D.

Dietary B-carotene and alpha-tocopherol combination dose not inhibit atherogenesis in an Apolipoprotein E-deficient mouse model.

In the proceedings of the Scientific Meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Ashkelon, Israel, 1998.

34. George, J., Harats, D., Afek, A., Gillburd, B., Shaish, A., Shoenfeld, Y.

The Role of Heat Shock Protein 65 (HSP) in Murine Atherosclerosis.

J.of Autoimmunity Suppl, 7, 1999

35. Harats, D., George, J., Gillburd, B., Afek, A., Shaish, A., Shoenfeld, Y.

β 2-Glycoprotein I (Apolipoprotein-H) as an Influential Determinant in Atherosclerosis.

J.of Autoimmunity Suppl, 7, 1999

36. Zurgil, N., Levy, Y., Deutsch, M., Gillburd, B., George, J., Harats, D., Kaufman, M., Shoenfeld, Y.

Reactivity of Peripheral Blood Lymphocytes (PBL) to oxLDL: A Novel System to Estimate Atherosclerosis Employing The Cellscan.

J.of Autoimmunity Suppl, 8, 1999

37. Harats, D., George, J., Afek, A., Gillburd, B., Shoenfeld, Y.

Administration of beta 2 glycoprotein I reduces atherogenesis in LDL-receptor-deficient mice.

In the proceedings of the 5th Int. Symposium: Multiple risk factors in cardiovascular disease, Venice, Italy, 19, 1999.

D.3. Abstracts and Proceedings. (cont.)

38. Leibovitz, E., Gavish, D., Roitelman, Y., Shaish, A., Harats, D.,
The association of GLN-ARG 192 and MET-LEU 54 polymorphism of human
paroxonase (PON1) gene with coronary artery disease in Israeli Jewish population.
In the proceedings of the 5th Int. Symposium: Multiple risk factors in cardiovascular
disease, Venice, Italy, 29,1999.

39. Shaish, A., Sherer, Y., Levkovitz, H., Shoenfeld, Y., Harats, D.
Magnesium fortification of drinking water suppresses atherogenesis in male LDL-
Receptor knockout mice
Atherosclerosis Suppl 96, May 1999.

40. Keren, P., George, J., Shaish, A., Levkovitz, H., Gilbrud, B., Janakovic, Z., Keren,
G., Shoenfeld, Y., Harats, D.
Combined hyperlipidemic hyperglycemic model of Atherosclerosis in Apo-E Deficient
Mice:
Atherosclerosis Suppl 97, May 1999.

41. George, J., Harats, D., Gillburd, B., Afek, A., Levy, Y., Shaish, A., Barshak, I.,
Shneiderman, J., Kopolovic, J., Shoenfeld, Y.
Immunolocalization of beta 2 glycoprotein I (Apolipoprotein-H) to human atherosclerotic
plaques: Potential implication for lesion progression.
Atherosclerosis Suppl 122, May 1999.

42. Harats, D., George, J., Gillburd, B., Afek, A., Shaish, A., Shoenfeld, Y.
Beta 2 glycoprotein I (Apolipoprotein-H) as an influential determinant in atherosclerosis.
Atherosclerosis Suppl 122, May 1999.

43. J. George , D. Harats , B. Guilburd , A. Afek , A. Shaish , Y. Shoenfeld.
 β -glycoprotein-1 (apolipoprotein-H) as an influential determinant in atherosclerosis.
IMAJ. 2(2): 33, 2000

44. N. Varda-bloom, A. Shaish, A. Gonen, S. Ferber, H. Levkovitz, D. Harats.
Vascular Specific Gene Therapy to Tumor Vascularization.
In the proceedings of the 3rd Annual meeting, American society of gene Therapy, Denver,
Colorado, June 2000.

45. P. Keren, A. Shaish, J. George, D. Harats
The effect of β -carotene and α -tocopherol supplementation on accelerated atherosclerosis
in diabetic apoE deficient mice
ATVB Suppl, Vol 151(1), Page 12, 2000.

46. N. Varda-bloom, A. Shaish, A. Gonen, H. Levkovits, D. Harats.
The PPE1 promoter as a tool for specific gene therapy to angiogenic vascular cells
ATVB Suppl, Vol 151(1), Page 101, 2000.

D.3. Abstracts and Proceedings. (cont.)

47. D. Harats, J. George, B. Gilburd, A. Afek, A. Shaish, Y. Shoenfeld.
Adoptive transfer of β 2-glycoprotein I reactive lymphocyte enhances atherosclerosis in LDL receptor deficient mice
ATVB Suppl, Vol 151(1), Page 166, 2000.
48. A. Afek, J. George, Y. Shoenfeld, B. Gilburd, D. Harats.
Cellular humoral immune responses to HSP 65 are both involved in promoting fatty streak formation in LDL –receptor deficient mice
ATVB Suppl, Vol 151(1), Page 189, 2000.
49. A. Shaish, D. Mirelman, D. Abramovitz, T. Miron, A. Rabinkov, M. Wilchek, M. Eldar, Z. Vered, H. Levkovitz, D. Harats
ATVB Suppl, Vol 151(1), Page 257, 2000.
50. J. George, Y. Shoenfeld, B. Gilburd, A. Afek, A. Shaish, D. Harats
A requisite role for IL-4 in the acceleration of fatty streaks induced by HSP65 or mycobacterium tuberculosis
ATVB Suppl, Vol 151(1), Page 190, 2000.
51. D. Harats, J. George, Y. Shoenfeld.
Autoantigens in Atherogenesis
The EAS workshop on the Immune System & atherosclerosis. Geneva, Switzerland March 2001.
52. D. Harats.
The Immune system in Atherosclerosis.
In the proceedings of the 37th Annual meeting of the EASD, Glasgow, Scotland, September 2001.
53. D. Harats.
The Immune system, Atherosclerosis and Diabetes..
In the proceedings of the International Diabetes and Atherosclerosis Symposium, Troon, Scotland, September 2001.
54. D. Harats.
The Immune system, Atherosclerosis and Diabetes..
In the proceedings of the American Diabetes Association Workshop, Tempe, Arizona, USA, September 2001.

G.1. Patent

1. Harats, D., Kurihara, H., Belloni, P., Sigal, E.

Using the murine preproendothelin-1 promoter to target gene expression to the vascular wall.

CASE 28100-P1, 1995, USA.

2. Harats, D., George, J., Shoenfeld, Y.

Oral Tolerance in Atherogenesis.

Filed in Israel September 1998.

3. Harats, D., George, J., Shoenfeld, Y.

A composition for the prevention and/or treatment of atherosclerosis.

PCT/IL99/00519 Filed September 1999.

4. Harats, D., Shoenfeld, Y., George, J.

The effect of mucosal tolerance with lipid lipoprotein and protein antigens on atherosclerosis in LDL-receptor deficient mice.

PCT/IL 01 Filed November 2001

5 Harats, D., George, J., Halperin, G.

Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis.

PCT/IL 01 Filed November 2001

6. Harats, D.

Using a Mini-Gene Construct (3X-PPR-1) for Endothelial Cells Specific Gene Therapy.

US Provisional Application No. 60/248,582 filed November 2000.

7. Harats, D.

Using a Mini-Gene Construct (3X-PPR-1) for Endothelial Cells Specific Gene Therapy.

PCT/IL 01 filed November 2001.

8. Harats, D., Grinberger Shoshana

Endothelial-specific apoptosis induced by an adenoviral vector containing TNFR1-Fas chimeric receptor driven by pre-proendothelin-1 promoter.

US Provisional Application filed September 2001.

SELECTED LIST OF PUBLICATIONS 2000-2001

B.1.37. Jacob George, Mary Mulkins, Aviv Shaish, Sharon Casey, Randall Schatzman, Elliott Sigal, Dror Harats.

IL-4 Deficiency does not Influence Fatty Streak Formation in C57BL/6 mice.
Atherosclerosis 153:403-411, 2000.

B.1.38. Dror Harats, Aviv Shaish, Jacob George, Mary Mulkins, Hiroki Kurihara, Hana Levkovitz and Elliott Sigal.

Overexpression of 15-Lipoxygenase in the Vascular Endothelium Accelerates Early Atherosclerosis in LDL Receptor-Deficient Mice.
Arteriosclerosis, Thrombosis and Vascular Biology 20(9):2100-5, 2000.

B.1.39. Pnina Keren, Jacob George, Aviv Shaish, Hana Levkovitz, Zora Janakovic, Arnon Afek, Iris Goldberg, Juri Koplovic, Gad Keren, Dror Harats.

Effect of Hyperglycemia and Hyperlipidemia on Atherosclerosis in LDL-Receptor Deficient Mice: Establishment of a Combined Model and Association with HSP65 Immunity.
Diabetes. (6):1064-9, 2000.

41. Halperin G, Elisaf M, Leitersdorf E and Harats D.

A new method for determination of serum cholestanol by high performance liquid chromatography with UV detection.
J.of Chromatography B. 742 (2): 345-352,2000

B.1.43. J. George, Y. Shoenfeld, B. Gilburd, A. Afek, A. Shaish and D. Harats.

Requisite role for IL-4 in the acceleration of fatty streaks induced by HSP 65 or *Mycobacterium Tuberculosis*.
Circ Res. 86(12):1203-1210, 2000.

B.1.44. **J. George* D. Harats***, B. Gilburd, A. Afek, A. Shaish, J. Kopolovic, and Y. Shoenfeld

Adoptive transfer of $\beta 2$ glycoprotein I ($\beta 2$ GPI)-reactive lymphocytes enhances early atherosclerosis in LDL receptor deficient mice.
Circulation 102:1822-1827, 2000.

***Both are first authors**

B.1.45. J. George, A. Afek, B. Gilburd, Y. Shoenfeld and D. Harats

Cellular and Humoral Immune response to HSP 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice.
JACC 38(3):900-905, 2001.

Selected list of publications (cont.)

B.1.49. Pnina Keren, Jacob George, Gad Keren, Dror Harats.

Non-Obese Diabetic (NOD) mice exhibit an increased cellular immune response to glycated-LDL but are resistant to high fat diet induced atherosclerosis
Atherosclerosis 157(2):285-292, 2001.

B.1.55. N. Varda-Bloom, A. Shaish, A. Gonen, K. Levanon, S. Greenbereger, S. Ferber, H. Levkovitz, A. Afek, Y. Kopolovitch, D. Harats.

Tissue-Specific Gene Therapy Directed to Tumor Angiogenesis.
Gene Therapy 8(11):819-827, 2001.


B.1.57. J. George, A. Afek, A. Shaish, H. Levkovitz, N. Bloom, T. Cyrus, L. Zhao, C. D. Funk, E. Sigal, D. Harats.

12/15-Lipoxygenase Gene Disruption Attenuates Atherogenesis in LDL-Receptor Deficient Mice.
Circulation 104(14):1646-1650, 2001.

B.1.64. A. Shaish, G. Keren, P. Chouraqui, H. Levkovitz, D. Harats.

Imaging of aortic atherosclerotic lesions by ¹²⁵I-LDL, ¹²⁵I-Oxidized-LDL, ¹²⁵I-HDL and ¹²⁵I-BSA.

Pathobiology (In-press).



PANEL II

ORAL
TOLERANCE

